News
Warnings issued for brentuximab vedotin
Two additional cases of progressive multifocal leukoencephalopathy (PML) have been reported with the lymphoma drug brentuximab vedotin (Adcetris...
News
HL drug demonstrates activity and toxicity
A novel agent has shown activity in relapsed or refractory Hodgkin lymphoma (HL), but it can cause severe adverse events and even death at a high...
News
Vaccine candidate reduces malaria risk
First results from a phase 3 trial of the vaccine candidate RTS,S/AS01 indicate it provides young African children with protection against...
News
FDA approves deferiprone to treat iron overload
The FDA has approved deferiprone (Ferriprox) to treat iron overload in thalassemia patients who had an inadequate response to prior chelation...
News
Team corrects SCD mutation with iPS cells
Using induced pluripotent stem (iPS) cells, researchers have corrected the genetic alteration that causes sickle cell disease (SCD). The...
News
Study supports lifting lifetime ban on MSM
The lifetime ban on blood donation from men who have sex with men (MSM) has been lifted in England, Wales, and Scotland. Beginning in November,...
News
Research indicates apixaban is superior to warfarin
These results were presented at the European Society of Cardiology Congress in Paris on August 28 and published simultaneously online in The New...
News
FDA grants accelerated approval for brentuximab vedotin
The US Food and Drug Administration (FDA) has granted accelerated approval for brentuximab vedotin (Adcetris) to treat patients with Hodgkin...
News
Brd4: Potential new target in AML
“The drug candidate not only displays remarkable anti-leukemia activity in aggressive disease models and against cells derived from patients with...
News
Rivaroxaban approved for thromboembolic events
Clinical studies evaluated the use of rivaroxaban in more than 6,000 patients.